Effect on the intestinal microbiome of ridinilazole vs vancomycin in patients with C. difficile infection

Antibiotics are not only the primary risk factor for the development of C. difficile infection but are also the standard treatment employed to eradicate it. C diff patients treated with vancomycin, the standard therapy, have a high rate of recurrence of infection (~25%), often requiring hospitalization. Ridinilazole is a C diff-targeted antibiotic which has a lower rate of recurrence.This study examined the effect on the intestinal microbiota of a 10 day course of treatment of C diff patients with either vancomycin or ridinilazole, with stool samples collected prior to treatment, after 5 days, at end of treatment, and 15 and 30 days after cessation of antibiotic.